I am a researcher specializing in highly pathogenic viruses (BSL3 and BSL4), with work experience in the laboratory and in the field (WHO) during the West Africa EBOV outbreak (2013 to 2016). I have a strong skill set in omics research, particularly proteomics, but also transcriptomics and have turned this into mechanistic functional studies. I received my Ph.D. from the University of Liverpool (UoL), UK, in 2016. Now, I am a fellow with the “Atraccion Talento Comunidad de Madrid”, working at the INIA–CSIC in Madrid, Spain. With more than 45 publications in several high-impact journals, my work has mainly focused on Ebola virus (EBOV), African swine fever virus (ASFV), and the pandemic virus SARS-CoV-2, where I have contributed to important research projects that have provided insight into fundamental biology concerning these three viruses. I have identified compounds that can be used as potential therapies for EBOV. These were discovered by studying the interactome of EBOV proteins. Using proteomic tools, I have also identified new potential cellular targets for ASFV and SARS-CoV-2 that are involved in viral replication, which functions can be inhibited to reduce viral infection. I am a member of the EMLab (European Mobile Laboratory), ISARIC (International Sever Acute Respiratory and Emerging Infection Consortium), and the Spanish Society of Virology and Society of General Microbiology (SGM) in the UK.
I am a researcher specializing in highly pathogenic viruses (BSL3 and BSL4), with work experience in the laboratory and in the field (WHO) during the West Africa EBOV outbreak (2013 to 2016). I have a strong skill set in omics research, particularly proteomics, but also transcriptomics and have turned this into mechanistic functional studies. I received my Ph.D. from the University of Liverpool (UoL), UK, in 2016. Now, I am a fellow with the “Atraccion Talento Comunidad de Madrid”, working at the INIA–CSIC in Madrid, Spain. With more than 45 publications in several high-impact journals, my work has mainly focused on Ebola virus (EBOV), African swine fever virus (ASFV), and the pandemic virus SARS-CoV-2, where I have contributed to important research projects that have provided insight into fundamental biology concerning these three viruses. I have identified compounds that can be used as potential therapies for EBOV. These were discovered by studying the interactome of EBOV proteins. Using proteomic tools, I have also identified new potential cellular targets for ASFV and SARS-CoV-2 that are involved in viral replication, which functions can be inhibited to reduce viral infection. I am a member of the EMLab (European Mobile Laboratory), ISARIC (International Sever Acute Respiratory and Emerging Infection Consortium), and the Spanish Society of Virology and Society of General Microbiology (SGM) in the UK.